Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBIT Margin (2020 - 2022)

Immuneering has reported EBIT Margin over the past 3 years, most recently at 3073627.91% for Q4 2022.

  • Quarterly results put EBIT Margin at 3073627.91% for Q4 2022, down 306776489.0% from a year ago — trailing twelve months through Sep 2023 was 12328770.77% (down 1231911324.0% YoY), and the annual figure for FY2022 was 16325.77%, down 1469661.0%.
  • EBIT Margin for Q4 2022 was 3073627.91% at Immuneering, down from 34362.04% in the prior quarter.
  • Over the last five years, EBIT Margin for IMRX hit a ceiling of 644.66% in Q3 2020 and a floor of 3073627.91% in Q4 2022.
  • Median EBIT Margin over the past 3 years was 1772.01% (2021), compared with a mean of 285392.02%.
  • Biggest five-year swings in EBIT Margin: plummeted -46060bps in 2021 and later crashed -306776489bps in 2022.
  • Immuneering's EBIT Margin stood at 877.56% in 2020, then crashed by -568bps to 5863.02% in 2021, then crashed by -52324bps to 3073627.91% in 2022.
  • The last three reported values for EBIT Margin were 3073627.91% (Q4 2022), 34362.04% (Q3 2022), and 12334.43% (Q2 2022) per Business Quant data.